ã¯ã¦ãªã°ã«ã¼ãã®çµäºæ¥ã2020å¹´1æ31æ¥(é)ã«æ±ºå®ãã¾ãã 以ä¸ã®ã¨ã³ããªã®éããä»å¹´æ«ãç®å¦ã«ã¯ã¦ãªã°ã«ã¼ããçµäºäºå®ã§ããæ¨ããç¥ãããã¦ããã¾ããã 2019å¹´æ«ãç®å¦ã«ãã¯ã¦ãªã°ã«ã¼ãã®æä¾ãçµäºããäºå®ã§ã - ã¯ã¦ãªã°ã«ã¼ãæ¥è¨ ãã®ãã³ãæ£å¼ã«çµäºæ¥ã決å®ãããã¾ããã®ã§ã以ä¸ã®éãã確èªãã ããã çµäºæ¥: 2020å¹´1æ31æ¥(é) ã¨ã¯ã¹ãã¼ãå¸æç³è«æé:2020å¹´1æ31æ¥(é) çµäºæ¥ä»¥éã¯ãã¯ã¦ãªã°ã«ã¼ãã®é²è¦§ããã³æ稿ã¯è¡ãã¾ãããæ¥è¨ã®ã¨ã¯ã¹ãã¼ããå¿ è¦ãªæ¹ã¯ä»¥ä¸ã®è¨äºã«ãããã£ã¦æç¶ãããã¦ãã ããã ã¯ã¦ãªã°ã«ã¼ãã«æ稿ãããæ¥è¨ãã¼ã¿ã®ã¨ã¯ã¹ãã¼ãã«ã¤ã㦠- ã¯ã¦ãªã°ã«ã¼ãæ¥è¨ ãå©ç¨ã®ã¿ãªãã¾ã«ã¯ãè¿·æãããããããã¾ãããã©ãããããããé¡ããããã¾ãã 2020-06-25 è¿½è¨ ã¯ã¦ãªã°ã«ã¼ãæ¥è¨ã®ã¨ã¯ã¹ãã¼ããã¼ã¿ã¯2020å¹´2æ28
ä¼æ¥ã®çµå¶è ã¯èªç¤¾ã®é¡§å®¢ãçç¥ããæ¢åäºæ¥ãå®ããã¨ãããããããç ´å£è ã¯æ¢åãã¸ãã¹ã¨ã¯å ¨ãç°ãªãäºæ¥å½¢æ ã§å¸å ´ã«åå ¥ãã¦ãããããåæã®æ®µéã§ã¯ãã£ã¹ã©ãã·ã§ã³ã ã¨æããããªãã誰ããããªãã®ã¨ããã«ãã£ã¦ãã¦ããææ¥ããªãã®ä¼ç¤¾ã®é¡§å®¢ãããã£ã¦ããããã¨åãããã¨ã¯ãªãããã åã«ãããªããããã¾ã§å¤§äºã«ãã¦ãã顧客ããä¸åº¦ã競åç¸æã¨è¦ãªãããã¨ã®ãªããã¬ã¼ã¤ã¼ã«çªå¦ã¨ãã¦ä¹ã移ã£ã¦ãã¾ãã®ã ããã®çç±ã¯å§åçãªä½ã³ã¹ããããããªããã製åã«å¯¾ããé¢å¿ã®å¤åãããããªãããããã«ããããã¯ããã¸ã¼ãæªæ¥ã«ä¸ããå¤åã注ææ·±ã観å¯ãã¦ããªãçµå¶è ã¯ããããã£ã¹ã©ãã·ã§ã³ãå§ã¾ã£ãã¨ãã«ã¯ãã¾ãã§ããã¾ã§ä½ãè¦ã¦ããªãã£ãããã«æããã ãããããã¦ããã®æç¹ã§ã¯ããæé ããªã®ã ã ã°ã¼ã°ã«Xã§ã®èªåé転è»éçºã¯å½åãæ ªä¸»ãªã©ããæ¹å¤ãæµ´ã³ããããã¯ã¡ããã©ãã°ã¼ã°ã«ãã¢ã³ããã¤ããè²·åã
2014å¹´8æãç±³ã°ã¼ã°ã«ã§ç´7å¹´éãèªåé転è»ã®éçºãçãã人工ç¥è½ï¼AIï¼ç 究è ã»ãã¹ãã£ã³ã»ã¹ã©ã³æ°ãå社ãå»ã£ãã ã¹ã©ã³æ°ã¯ç±³ã¹ã¿ã³ãã©ã¼ã大å¦ã®AIç 究æé·ã ã£ã2005å¹´ã«ãç±³å½é²é«çç 究è¨ç»å±ï¼DARPAï¼ãéå¬ããããããã«ã¼ã¬ã¼ã¹ã§åã®å®èµ°ãæãããå¾ãã°ã¼ã°ã«ã«åç»ãå社ã®ç§å¯ç 究æãã°ã¼ã°ã«Xããåµè¨ããã¨ãèªåé転è»ã®ä»ãã¡ã¬ãå端æ«ãã°ã¼ã°ã«ã°ã©ã¹ããªã©æ°ã ã®ç 究è¨ç»ãç«ã¡ä¸ãã¦ããã åæ°ã¯ã°ã¼ã°ã«ãé¢ããçç±ãã2011å¹´ã«èªèº«ãåµæ¥ãããªã³ã©ã¤ã³æè²ä¼æ¥ã»ç±³ã¦ãã·ãã£ã¼ã®çµå¶ã«å°å¿µããããã ã¨èª¬æãããã¦ãã·ãã£ã¼ã¯ã¤ã³ã¿ã¼ããããéãã¦å¤§å¦ã¬ãã«ã®è¬ç¾©ãé ä¿¡ããMOOCï¼å¤§è¦æ¨¡å ¬éãªã³ã©ã¤ã³è¬åº§ï¼ã®å é§ãçä¼æ¥ãã¹ã©ã³æ°ãå°éã¨ããAIã®ã»ãããã¼ã¿è§£æãã¢ããªéçºãªã©60ç§ç®ä»¥ä¸ãé ä¿¡ããç»é²è æ°ã¯ä¸çã§300ä¸äººãè¶ ããã èªåé転ã®ç¬¬ä¸äººè ã¯AIã®
For the first time, an off-the-shelf CAR T cell therapy has been used to treat potentially life-threatening autoimmune disorders in three people. With a...
A I ( Artificial Intelligence ) ï¼äººå·¥ç¥è½ã«é¢ããã·ãªã¼ãºã¨ã³ããªãæçµåã§ãã ï¼ã·ãªã¼ãºã¨ã³ããªä¸è¦§ï¼ 第ä¸åããA I ï¼äººå·¥ç¥è½ï¼ãï¼å¬ã®æ代ãè¶ ãã¦ï¼ 第äºåããA I éçºãï¼æ°ãã主役ã®ç»å ´ï¼ 第ä¸åããA I ã®ããçæ´»ãï¼ã¤ã¡ã¼ã¸ç·¨ï¼ 第ååããA I ã¯æãï¼ ç¬¬äºåããããã°ãã¼ã¿ã¨ A I 第å åããã·ã³ã®ã¥ã©ãªã㣠㻠æè¡çç¹ç°ç¹ãï¼ã¾ãï¼ï¼ ä»æ¥åãä¸ããã®ã¯ãã·ã³ã®ã¥ã©ãªãã£ã ï¼ Singularity ãæ¥æ¬èªã§ã¯ âæè¡çç¹ç°ç¹â ï¼ã¨ããè¨èã ç±³å½ã®æ°å¦è ï¼ï¼ SF ä½å®¶ï¼ã§ããã´ã¡ã¼ãã¼ã»ã´ã£ã³ã¸æ°ã 20å¹´ã»ã©åããæå±ãã¦ãæªæ¥ææ³ã§ããããããã³ã³ãã¥ã¼ã¿ãå é度çã«é²åããæ©æ¢°ã¯ããã人é以ä¸ã®ç¥è½ã¨ã人éã¨åæ§ã®âæèâã¾ã§æã¤ããã«ãªããã£ã¦ãã¨ããããã¯ãã®æç¹ã®ãã¨ãã ããã§ãã ãªãã§ãæè¡çç¹ç°
ã·ãªã³ã³ãã¬ã¼ã®ä¸å¿ã«ããç±³èªç©ºå®å®å±ï¼NASAï¼ã®åºå¤§ãªãªãµã¼ããã¼ã¯ãã·ã³ã®ã¥ã©ãªãã£å¤§å¦ï¼SUï¼ã¯ãã®ä¸è§ã«ãããæè¡é©æ°ããã³ã«é£ç³§ãã¨ãã«ã®ã¼ãªã©ä¸ççãªé£é¡è§£æ±ºã«æã人æãè²ã¦ãå大å¦ã訪ãã¦ã¿ããæè¡ã®å ¨ä½åãå¦ã¹ãå ´ææ¬é¨ãã«ããå°ãé¢ããå¹³å±ã®å»ºç©ã«ããã®ããã¤ããã¼ã·ã§ã³ã»ã©ããã ã足ãè¸ã¿å ¥ããã¨ã3Dï¼3次å ï¼ããªã³ã¿ã¼ãå°åç¡äººæ©ãããåããããããã¼ãã£ã«ãªã¢ãªã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}